Doctor of Podiatric Medicine Program year 2023 Reported 2020–2023 Source: CMS Open Payments, 2026 publication

Smitha Mantha

Podiatrist Houston, TX Doctor of Podiatric Medicine

NPI 1689808479 CMS profile 212919

8968 Kirby Dr, Houston, TX 77054

Open in the dashboard

General payments

$1,370

23 records reported · program years 2020–2023

Research payments

$0

Paid to them · None reported · program years 2020–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$68,055 paid to institutions, not to them · program years 2023–2025

Through program year 2023, Smitha Mantha of Houston, TX is reported in the CMS Open Payments database as having received $1,370 across 23 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $68,055 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 59th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $557 9
2022 General $469 6
2021 General $295 5
2020 General $50 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Smitha Mantha
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Smitha Mantha were reported at $0. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Smitha Mantha Podiatrist median Middle half National median
2019 $0 $196 $72–$601 $163
2020 $50 $118 $38–$335 $114
2021 $295 $169 $57–$573 $132
2022 $469 $220 $74–$782 $149
2023 $557 $208 $71–$635 $160
2024 $0 $237 $87–$681 $164
2025 $0 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2020–2023
  1. Stryker Corporation $282 4 payments
  2. Davol Inc. $239 1 payment
  3. Organogenesis Inc. $158 3 payments
  4. Corium, Inc. $122 1 payment
  5. Bioventus LLC $120 1 payment
  6. Trilliant Surgical LLC. $102 1 payment
  7. Vaporox, Inc. $78 1 payment
  8. Pacira Pharmaceuticals Incorporated $72 1 payment
  9. Abbott Laboratories $61 3 payments
  10. Treace Medical Concepts, Inc. $51 2 payments
  11. Other $86 5 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2023
  1. Food and Beverage $1,370 23 payments
Products named General payments · program years 2020–2023
  1. ARISTA AH FLEXITIP $239 1 payment
  2. AUGMENT INJECTABLE $190 2 payments
  3. Puraply $158 3 payments
  4. ADLARITY $122 1 payment
  5. Exogen Ultrasound Bone Healing System $120 1 payment
  6. Minimally Invasive Bunion Plate, Left $102 1 payment
  7. VHT-200 Wound Treatment System $78 1 payment
  8. Iovera System $72 1 payment
  9. ANCHORAGE $69 1 payment
  10. LAPIPLASTY SYSTEM $51 2 payments
  11. Other $184 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

189

Median for Podiatry: 160

Drug cost

$2,863

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ammonium Lactate Generic 72 $1,950
Clotrimazole Generic 65 $531
Gabapentin Generic 17 $149
Mupirocin Generic 20 $139
Methylprednisolone Generic 15 $93

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$49,468

Medicare's payments for the services billed

Medicare patients

19

Average age 66

Services billed

136

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record